WO 2017/181118 Al 19 October 2017 (19.10.2017) P O P C T
Total Page:16
File Type:pdf, Size:1020Kb
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/181118 Al 19 October 2017 (19.10.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 311/74 (2006.01) C07C 69/708 (2006.01) kind of national protection available): AE, AG, AL, AM, C07C 69/017 (2006.01) C07C 219/04 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07C 271/44 (2006.01) C07C 229/12 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C07C 271/52 (2006.01) C12M 1/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07D 311/80 (2006.01) C12M 1/40 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, C07C 69/675 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (21) International Application Number: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, PCT/US20 17/027776 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (22) International Filing Date: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 14 April 2017 (14.04.2017) ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/323,296 15 April 2016 (15.04.2016) TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/327,212 25 April 2016 (25.04.2016) DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicant: FULL SPECTRUM LABORATORIES LTD SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, [IE/IE]; One Earlsfort Centre, Lower Hatch Road, Suite 3, GW, KM, ML, MR, NE, SN, TD, TG). Dublin 2 (IE). Published: (72) Inventors; and — with international search report (Art. 21(3)) (71) Applicants : PEET, Ricard C. [US/US]; 12005 Whit- marsh Lane, Tampa, Florida 33626 (US). KAVARANA, — before the expiration of the time limit for amending the Malcolm J. [US/US]; 12005 Whitmarsh Lane, Tampa, claims and to be republished in the event of receipt of Florida 33626 (US). amendments (Rule 48.2(h)) (74) Agents: PERDOK, Monique M. et al; SCHWEGMAN LUNDBERG & WOESSNER, P.A., P.O. Box 2938, Min neapolis, Minnesota 55402 (US). < 00 00 o (54) Title: BIOSYNTHESIS OF CANNABINOID PRODRUGS (57) Abstract: The present invention provides methods for producing cannabinoid prodrugs. Also described are pharmaceutically acceptable compositions of the prodrugs and a system for the large-scale production of the prodrugs. [0001] This application claims the benefit of priority to U.S. Provisional Application No. 62/323,296, filed April 15, 2016; This application also claims the benefit of priority to U.S. Provisional Application No. 62/327,212, filed April 25, 2016, the contents of which are incorporated in their entirety in the present application. FIELD OF THE INVENTION [0002] The present invention relates to the biosynthesis of pharmaceutically acceptable prodrugs of cannabinoids. Also described is the production and manipulation of enzymes involved in the synthesis of cannabinoids, and the surprising discover}- that pH influences the ratio of cannabinoid prodrugs produced using the inventive methods. BACKGROUND OF THE INVENTION [0003] Cannabinoids are terpenophenolic compounds found in Cannabis sativa, an annual plant belonging to the Cannabaceae family. The plant contains more than 400 chemicals and approximately 70 cannabinoids. The latter accumulate mainly i the glandular trichomes. The most active of the naturally occurring cannabinoids is tetrahydrocannabinol (THC), which is used for treating a wide range of medical conditions, including glaucoma, AIDS wasting, neuropathic pain, treatment of spasticity associated with multiple sclerosis, fibromyalgia and chemotherapy -induced nausea. THC is also effective in the treatment of allergies, inflammation, infection, epilepsy, depression, migraine, bipolar disorders, anxiety disorder, drug dependency and drug withdrawal syndromes. [0004] Additional active cannabinoids include cannabidiol (CBD), an isomer of THC, which is a potent antioxidant and anti-inflammatory compound known to provide protection against acute and chronic neuro-degeneration. Cannabigerol (CBG), is another cannabinoid found in high concentrations in hemp. CBG is a high affinity a2-adrenergic receptor agonist and a moderate affinity 5-Η Τ Α receptor antagonist. CBG is a low affinity CB1 receptor antagonist, and has anti-depressant activity [0005] Cannabichromene (CBC), another phytocannabinoid possesses anti-inflammatory, anti-fungal and anti-viral properties. Phytocannabinoids have been used as therapeutics to treat a variety of diseases and in plants may play a similar role in the plant's defense mechanisms against disease causing agents. [0006] Despite their known beneficial effects, therapeutic use of cannabinoids is hampered by the high costs associated with growing and maintaining plants on a large scale and the difficulty in extracting, isolating and purifying cannabinoids from plant tissues. [0007] There exists a need, therefore, for developing methodologies that allow large-scale production of cannabinoids and cannabinoid prodiugs in quantities required for therapeutic use. The present invention addresses this need. SUMMARY [0008] The present invention provides methods for synthesizing prodrugs of cannabinoids. Also described are representative examples of the inventive prodrugs which can be administered to patients in need of cannabinoid based therapy, for example for treating conditions such as glaucoma, chronic pain, AIDS and in the treatment of cancers. [0009] In one embodiment, the present invention provides a method for producing a prodrug of a cannabinoid of Formula II or Formula III: Formula I with a cannabinoid synthase to produce a compound according to Formula Π or Formula III; and (b) optionally decarboxylating the Formula II or Formula III compound. [0010] For Formula I, Formula II and Formula III compounds, substituents R and R3 are each independently selected from the group consisting of-H, acetyl, propionvl, 3-hydroxy - 2-methylpropionyl, F NIS. TBDMS, benzyl, -C(0)[CH ]x-C(0)QH, -C(0)[CH ]x-OR4, 4 5 6 4 -C(0)[CHR.4]x-C(0)OH, -C(0)[Cim ]x-OR , ~C(0)[CR R ]x~OR , ~C(0)0[CH 2 ]x-OR , 4 ] x 4 4 5 ~C(Q)-CH2-[OCH 2CH2]x-QR , -C(0)-C(0)-[OCH 2CH2 -OR , -C(0)[CH2Jx R R , 4 5 5 + 5 -C(0)0[CH 2 ]x-NR R , -C(0)-NH -[CH2]x-NR R , -C(0)[CH 2 ]x-N (R )(R ) )(R )X + 4 5 6 + 4 5 -C(0)0[CH 2 ]x-N (R )(R ) )(R )X -C(0)-NH-[CH2 ]x-N (R )(R ) )(R )X a ,-amino acid residue, a D-amino acid residue, a β-amino acid residue, a γ-amino acid residue, -P(0)[OY](OZ), and (0 ) R4 R ][OY] . [0011] Substituent R in Formula I, Formula II and Formula III is -H, -COOH, -COOR ', , 2 o (C ' ,C()(}] while R is selected from the group consisting of (C 1-C 10)alkyl, (C 2-Cio)alkeny1, (C2-Cio)alkyny1, (C -Cio)cycloalky 1, (C -Cio)cycloalkylalkylene, (C3 -Cio)aiyl, and (C -C 10 )arylalkylene. [0012] For some Formula II or Formula II compounds substituent R or R3 is 4 5 5 6 4 -C(Q)[CHR4]x-C(Q)OH, -C(Q)[CHR ]X-QR , -C(0)[CR R x-OR , -C(0)0[CH 2]x-OR , ]x 4 4 -C(0)-CH -[OCH 2CH2 -OR , or ~C(0)-C(0)-[OCH CH ]x~OR . For such compounds, substituents R4 and R5 each independently are -NH , -NH(CH ), - (( Ί ( or 4 5 N(CH3)2 . For certain other Formula II or III compounds, substituents R and R are each independently -H or a (Ci-C ky , for example, methyl, ethyl propyl, butyl or t-butyl. [0013] Substituents R4, R5, and R are each independently selected from the group 4 consisting of-H, -OH, formyl, acetyl, pivaloyl, and (C 1-Cs)alkyl. In one embodiment R 5 4 and R , are each independently -H or a (C 1-C5)alk 'l and the group - R R- is -NH2, - {{ ' I·;), -NH(CH CH3), or Ί ·}' According to another embodiment, either R4 and R5 5 is formyl or acetyl and the group - R R is -NH[C(0)H], and -NH[C(0)CH 3]. Substituent Ra is a (C -Cio)alkyl, for example, methyl, ethyl or t-butyl for Formula I, II and III compounds. [0014] For some Formula I, Formula II and Formula III compounds variable "X" is a counter ion derived from a pharmaceutically acceptable acid while variables "Y" and "Z" are each independently selected from the group consisting of-H, (Ci-Cs)alkyl, alkali metal cations, alkaline earth metal cations, ammonium cation, methyl ammonium cation, and pharmaceutically acceptable bases. For compounds in accordance with the invention, subscripts "x" and "n" are selected from the group consisting of 0 , 1, 2 , 3 , 4 , 5 , and 6 . [0015] In one embodiment, for compounds in accordance with the invention, substituent R is selected from the group consisting of -C(0 )[CH 2 ] -C(0 )OH, -C )[C! k- R ]x 5 4 1 2 -C(0)[CH 2 - R R , and -C(0)-CH 2-[OCH2C¾]x-OR , substituent R is --COOH, and R is (Ci-Cio)alkyl, for example, a propyl or a pent l group.